Last updated: September 25, 2026
ALK-Abelló A/S is a Denmark-based specialty pharmaceutical company focused on allergy immunotherapy, particularly sublingual immunotherapy tablets and subcutaneous allergy extracts. Its core commercial assets include Grazax/Grastek for grass-pollen allergy, Itulazax for tree-pollen allergy, Acarizax/Odactra for house-dust-mite allergy, and allergy extract products sold through specialist channels.
ALK’s competitive position is strongest in standardized allergen immunotherapy, where regulatory know-how, clinical evidence, physician relationships, manufacturing controls, and reimbursement access create higher barriers than conventional small-molecule generic markets. Its main strategic risks are concentration in allergy immunotherapy, reimbursement pressure, product-specific patent expiry, seasonal demand, and competition from Stallergenes Greer, Merck, and non-pharmaceutical allergy treatments.
What is ALK-Abelló’s market position in allergy immunotherapy?
ALK is one of the largest dedicated allergy immunotherapy companies globally. Its portfolio covers sublingual tablets, subcutaneous immunotherapy extracts, emergency epinephrine products, and selected allergy diagnostics.
The company’s core business is disease-modifying allergy treatment rather than symptom control. Antihistamines, intranasal corticosteroids, leukotriene modifiers, biologics such as omalizumab, and allergen avoidance products compete for the same patient and payer budgets but do not generally provide the same immunologic treatment objective.
ALK-Abelló’s principal products
| Product |
Active allergen or ingredient |
Delivery |
Principal indication |
Key markets |
| Grazax |
Timothy grass pollen allergen extract |
Sublingual tablet |
Grass-pollen allergic rhinitis |
Europe and selected international markets |
| Grastek |
Timothy grass pollen allergen extract |
Sublingual tablet |
Grass-pollen allergic rhinitis |
United States |
| Itulazax |
Birch homologous group pollen extract |
Sublingual tablet |
Tree-pollen allergic rhinitis |
Europe |
| Acarizax |
House-dust-mite allergen extract |
Sublingual tablet |
House-dust-mite allergic rhinitis and asthma |
Europe and international markets |
| Odactra |
House-dust-mite allergen extract |
Sublingual tablet |
House-dust-mite allergic rhinitis |
United States |
| Jext |
Epinephrine |
Auto-injector |
Anaphylaxis emergency treatment |
Europe and selected markets |
| Allergy extracts |
Various standardized and non-standardized allergens |
Subcutaneous or other administration |
Allergy immunotherapy |
Europe, North America and other markets |
ALK’s tablet platform is commercially important because it converts allergy immunotherapy from a clinic-administered injection model into a prescription product that can be administered at home after the first dose under medical supervision.
In fiscal 2023, ALK reported revenue of approximately DKK 4.6 billion, with continued growth from tablet-based allergy immunotherapy and international expansion. The company’s stated long-term strategy centers on expanding tablet penetration and increasing treatment of patients who remain undertreated with conventional allergy medicines (ALK-Abelló, 2024).
How does ALK-Abelló compare with its main competitors?
ALK competes in a fragmented market, but the most relevant direct competitor is Stallergenes Greer. Merck is also strategically important because it commercializes Odactra in the United States under a relationship with ALK.
| Company |
Core position |
Key products or capabilities |
Competitive advantage |
| ALK-Abelló |
Allergy immunotherapy specialist |
Grazax, Grastek, Itulazax, Acarizax, Odactra, extracts |
Broad standardized tablet and extract portfolio |
| Stallergenes Greer |
Allergy immunotherapy specialist |
Oralair, Staloral, allergen extracts |
Established European and U.S. presence |
| Merck |
Large pharmaceutical company and U.S. commercial partner |
Odactra in the U.S. |
U.S. commercial infrastructure and payer access |
| Sanofi/Regeneron |
Allergy and immunology competitor |
Dupixent in relevant type 2 inflammatory diseases |
Biologic efficacy in severe asthma and related disease |
| AstraZeneca |
Respiratory and allergy competitor |
Biologic respiratory portfolio |
Specialist physician access and biologic infrastructure |
| Generic and OTC manufacturers |
Symptom-control competitors |
Antihistamines, nasal steroids and combination products |
Low price and broad pharmacy distribution |
How does ALK compare with Stallergenes Greer?
ALK has a stronger position in standardized allergy immunotherapy tablets and an extensive European regulatory footprint. Stallergenes Greer competes through Oralair, subcutaneous immunotherapy products, and allergen extracts.
The two companies face similar structural issues:
- Long treatment durations, often approximately three years.
- Physician and patient adherence requirements.
- Seasonal initiation windows for pollen products.
- Reimbursement differences by country.
- Manufacturing complexity related to allergen standardization.
- Limited interchangeability between allergen extracts.
ALK’s differentiation is based on product breadth, clinical evidence, tablet scale, and experience with regulatory approval for disease-modifying allergy products. Stallergenes Greer remains a material competitor in both tablets and extracts, particularly in Europe and North America.
What patents protect ALK-Abelló allergy immunotherapy products?
ALK’s protection is based on several layers rather than one universal patent covering the entire business:
- Product and composition patents covering allergen extracts or standardized allergen preparations.
- Pharmaceutical formulation patents covering tablet composition, excipients, stability, dissolution and dose delivery.
- Method-of-use patents covering treatment of specific allergic diseases or patient populations.
- Manufacturing and quality-control know-how covering allergen sourcing, extraction, standardization and release testing.
- Regulatory exclusivity and clinical data protection.
- Trademarks and brand recognition.
The strongest practical protection often comes from the combination of patents, proprietary manufacturing specifications, clinical datasets, physician familiarity and regulatory complexity.
Representative product protection profile
| Product family |
Patent and exclusivity profile |
Principal competitive issue |
| Grazax/Grastek |
Core product patents have finite lives; later formulation and method patents may provide additional protection in some jurisdictions |
Generic or follow-on tablet substitution |
| Acarizax/Odactra |
Product, formulation and method-of-use protection vary by country and regulatory filing |
U.S. Orange Book listing and ANDA/Paragraph IV risk |
| Itulazax |
Newer product lifecycle than early grass-pollen tablets in several markets |
Expansion of label and geographic coverage |
| Allergy extracts |
Protection relies heavily on manufacturing know-how, standards, supply controls and trademarks |
Limited direct substitution but variable regulatory barriers |
| Jext |
Device, formulation and regulatory protection are separate from immunotherapy products |
Competing epinephrine auto-injectors |
Patent expiry must be reviewed by product, country, dosage form and patent family. Expiry of an early composition patent does not automatically eliminate protection from later formulation or method-of-use claims.
What is the Orange Book status of ALK’s U.S. products?
ALK-related U.S. allergy immunotherapy products include Grastek and Odactra. Grastek is associated with the timothy-grass sublingual tablet marketed in the United States. Odactra is the U.S. house-dust-mite sublingual tablet.
The U.S. Orange Book is relevant because it identifies patents submitted by NDA holders for approved drug products. A generic applicant can file an abbreviated new drug application with a Paragraph IV certification against listed patents. That certification can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework.
Orange Book risk for allergy immunotherapy is more complex than for a conventional tablet because:
- The active material is a standardized allergen extract rather than a conventional chemically defined molecule.
- Clinical and analytical equivalence can be difficult to establish.
- Allergen potency and composition may depend on biological source material.
- A competitor may need a full NDA or another regulatory strategy rather than a straightforward ANDA.
- Method-of-use patents can remain relevant even after an earlier product patent expires.
ALK’s U.S. product risk should be assessed through current FDA Orange Book entries, patent-family prosecution history, ANDA certifications and litigation dockets. The existence of an Orange Book-listed patent does not by itself establish that the patent will survive validity or infringement challenges.
When do ALK-Abelló products lose exclusivity?
There is no single ALK exclusivity date. Each product has a separate timeline.
| Exclusivity element |
Relevance to ALK |
| Patent term |
Generally measured from the earliest effective non-provisional filing date, subject to patent-term adjustment or extension |
| New chemical entity exclusivity |
Usually less relevant for allergen extracts than for conventional new molecular entities |
| Clinical investigation exclusivity |
May apply to certain supplemental approvals or pediatric studies |
| Orphan exclusivity |
Generally not the central protection mechanism for ALK’s principal products |
| Data and market exclusivity |
More relevant in Europe and other jurisdictions for newer approvals |
| Trademark protection |
Can continue indefinitely through renewal and commercial use |
| Manufacturing know-how |
Has no fixed statutory expiry and can remain valuable after patent expiry |
The earliest commercial tablet products face greater lifecycle pressure than Itulazax and newer indication expansions. However, loss of patent protection does not necessarily produce immediate generic entry. A competitor must obtain regulatory approval, demonstrate product quality, secure allergen supply and establish payer and physician acceptance.
What generic entry risks exist for ALK-Abelló?
The principal generic entry risk is concentrated in mature sublingual tablet products. The risk is lower than for a typical small-molecule tablet because the active ingredient is a biological allergen preparation with product-specific potency and composition.
Generic entry scenarios
| Scenario |
Timing |
Commercial effect |
| No approved competitor after patent expiry |
Near-term after expiry |
Continued branded sales, with price pressure from payer negotiations |
| Authorized or licensed equivalent |
Following regulatory approval |
Moderate price erosion and channel pressure |
| ANDA with Paragraph IV challenge |
Before listed-patent expiry |
Litigation, possible 30-month stay and launch uncertainty |
| Full NDA or hybrid application |
Longer development cycle |
Higher cost and slower competitive entry |
| Competing allergen tablet |
Does not require direct equivalence |
Share loss without formal generic substitution |
| OTC or prescription symptom treatment |
Immediate availability |
Patient switching, particularly where reimbursement is weak |
The most credible competitive threat may be a competing allergy immunotherapy product rather than a chemically identical generic. Oralair, for example, competes for pollen-allergy patients even though it is not a generic version of Grastek.
Which companies are challenging ALK-Abelló’s products?
The competitive landscape includes both direct immunotherapy providers and therapeutic substitutes.
Stallergenes Greer is the principal direct specialist competitor. Its Oralair product competes with grass-pollen tablets, while its extract portfolio competes with ALK’s subcutaneous products.
Merck has commercial significance in the United States through Odactra. This relationship gives the product access to Merck’s regulatory, medical and commercial infrastructure, while ALK remains central to product technology and supply.
Sanofi and Regeneron compete in severe allergic and type 2 inflammatory disease through Dupixent. Biologics are not direct substitutes for all patients receiving allergy immunotherapy, but they can compete for patients with severe asthma, atopic dermatitis or chronic rhinosinusitis.
Antihistamine and intranasal-steroid manufacturers compete for the larger symptom-control market. These products are cheaper, familiar to patients and available without specialist immunotherapy visits.
Does ALK-Abelló face biosimilar risk?
ALK does not face a conventional biosimilar threat to its main allergy immunotherapy tablets because the products are allergen extracts rather than monoclonal antibodies or other therapeutic biologics regulated through the biosimilar pathway.
The company does face biologic substitution risk indirectly. Dupixent and other type 2 inflammatory biologics may reduce the addressable population for allergy immunotherapy in patients whose primary clinical need is severe asthma or multi-system allergic inflammation.
This distinction matters:
- Biosimilars could pressure competing biologic therapies.
- They do not automatically create substitutes for ALK’s allergen tablets.
- Competing allergen immunotherapy products and conventional allergy drugs remain the more direct threats.
What manufacturing and intellectual-property barriers protect ALK?
ALK’s manufacturing capabilities are strategically important because allergen products require consistent biological source material, validated extraction, potency testing and controlled batch release.
Key barriers include:
- Access to high-quality allergen source materials.
- Standardization of allergen potency.
- Analytical methods for major allergen content.
- Control of batch-to-batch variability.
- Stability and storage validation.
- Regulatory documentation across multiple jurisdictions.
- Clinical evidence linking the product’s dose to disease modification.
- Specialized quality systems for allergen products.
These barriers do not create permanent exclusivity. They increase the time, cost and regulatory risk of a competing product and can delay practical market entry after patent expiry.
What licensing deals affect ALK-Abelló?
ALK’s U.S. commercial position has been shaped by its relationship with Merck for house-dust-mite allergy immunotherapy. Odactra was developed from ALK’s technology and commercialized in the United States through Merck’s pharmaceutical platform.
The relationship illustrates a broader strategic model:
- ALK contributes allergen-immunotherapy technology, clinical development and manufacturing expertise.
- A large pharmaceutical partner contributes U.S. commercialization, market access, medical affairs and distribution.
- Economic value is divided through collaboration and commercialization arrangements rather than through full internal commercialization in every market.
ALK also sells products directly in many European markets, where its local regulatory and physician infrastructure is stronger.
What patent litigation affects ALK-Abelló?
Publicly disclosed risk is more likely to arise through product-specific U.S. Orange Book challenges, ANDA certifications and patent disputes than through broad litigation over ALK’s entire platform.
The most relevant litigation questions are:
- Whether a listed patent claims the product, formulation or approved method of use.
- Whether a generic applicant has filed a Paragraph IV certification.
- Whether the NDA holder initiates litigation within the statutory period.
- Whether the court grants or maintains a 30-month stay.
- Whether the patent survives validity, written-description, enablement and obviousness challenges.
- Whether the competing product can launch with a skinny label that omits patented indications.
A patent estate can remain commercially effective even when individual claims are vulnerable. The practical outcome depends on the number of remaining patents, the scope of the approved label, regulatory requirements and the competitor’s launch economics.
How strong is ALK-Abelló’s patent estate?
ALK’s patent estate is strongest when viewed as an integrated package of patents, data, manufacturing know-how and regulatory barriers.
| Strength factor |
Assessment |
| Product differentiation |
Strong in disease-modifying allergy immunotherapy |
| Manufacturing barriers |
Strong, particularly for standardized allergen extracts |
| Composition patents |
Product-specific and subject to age-related erosion |
| Formulation protection |
Important for tablet integrity, dosing and stability |
| Method-of-use protection |
Potentially valuable but vulnerable to label carve-outs |
| Regulatory complexity |
Higher than for conventional generic tablets |
| Trademark value |
High for established products and physician recognition |
| Long-term exclusivity |
Uneven because early tablet products mature at different times |
The estate is commercially durable but not immune to erosion. Older products face the greatest patent and reimbursement pressure. Newer products and expanded indications provide lifecycle support, but their value depends on adoption and payer coverage.
What revenue exposure does ALK-Abelló have to patent expiry?
ALK’s revenue exposure is concentrated in allergy immunotherapy tablets and related extract products. A material reduction in branded tablet pricing could affect gross margin disproportionately because established products generally carry higher contribution margins than newer launches or lower-priced extract products.
The financial impact of patent expiry would depend on:
- Whether a true generic enters.
- The number of competing allergy tablets.
- Payer substitution rules.
- The extent of price discounting.
- Patient adherence to multi-year therapy.
- New indication uptake.
- Geographic mix.
- Continued growth in untreated allergy populations.
A gradual erosion scenario is more plausible than an immediate collapse because allergen products are difficult to substitute automatically and physician initiation remains important.
How does ALK-Abelló compare with conventional allergy drugs?
| Category |
ALK allergy immunotherapy |
Antihistamines and nasal steroids |
Biologics |
| Treatment objective |
Disease modification |
Symptom control |
Disease control in severe disease |
| Administration |
Often daily tablets for years |
Daily or as-needed |
Injection or infusion |
| Cost |
Higher upfront and cumulative cost |
Low |
High |
| Generic substitution |
Technically complex |
Common |
Biosimilar pathway increasingly relevant |
| Specialist involvement |
Usually required |
Limited |
Usually required |
| Adherence challenge |
Long duration |
Variable |
Clinic or injection burden |
| Market access |
Reimbursement-sensitive |
Broad OTC or prescription access |
Prior authorization and specialist criteria |
ALK’s products occupy a specialized position between low-cost symptom control and high-cost biologic therapy.
Key Takeaways
- ALK-Abelló A/S is a leading specialist in allergy immunotherapy, not a conventional diversified pharmaceutical company.
- Its core competitive assets are sublingual allergy tablets, standardized extracts, clinical evidence and manufacturing expertise.
- Stallergenes Greer is the main direct competitor; Merck is strategically important through U.S. commercialization of Odactra.
- Patent protection is product-specific and includes composition, formulation, method-of-use and manufacturing-related rights.
- U.S. Orange Book and Paragraph IV exposure should be assessed separately for Grastek and Odactra.
- ALK does not face a direct biosimilar threat to its principal allergen tablets, but biologics compete indirectly for severe allergic-disease patients.
- Generic entry is difficult but not impossible because allergen potency, standardization and regulatory equivalence create technical barriers.
- Mature tablet products carry the greatest exclusivity and pricing risk.
- ALK’s strongest long-term protection comes from the combined effect of patents, know-how, regulatory records, supply controls and physician adoption.
FAQs
Is ALK-Abelló a biologics company?
No. ALK-Abelló primarily develops and manufactures allergen extracts and sublingual immunotherapy tablets. Its products are biological in source material but are not generally treated as monoclonal-antibody biologics subject to conventional biosimilar competition.
Does Merck own ALK-Abelló’s Odactra technology?
No. Odactra is based on ALK’s allergy-immunotherapy technology and is commercialized in the United States through a relationship with Merck. Ownership, licensing and economic rights depend on the governing collaboration agreements.
Can generic companies substitute for Grastek or Odactra automatically?
Automatic substitution is less straightforward than for a conventional chemically defined tablet. Regulatory approval, allergen standardization, potency and product-specific labeling can limit direct substitution.
Are ALK-Abelló’s allergy tablets reimbursed in Europe?
Coverage varies by country, indication, age group and national reimbursement policy. Some markets reimburse allergy immunotherapy, while others impose patient co-payments or restrict coverage to defined clinical criteria.
What is ALK-Abelló’s most important strategic risk?
The main risk is the combination of product maturity and reimbursement pressure. Patent expiry alone may not cause rapid substitution, but lower pricing, competing immunotherapy tablets, reduced specialist initiation and long treatment-duration adherence can weaken revenue growth.
References
-
ALK-Abelló A/S. (2024). Annual report 2023. ALK-Abelló A/S.
-
European Medicines Agency. (n.d.). Acarizax: EPAR product information. European Union.
-
European Medicines Agency. (n.d.). Itulazax: EPAR product information. European Union.
-
U.S. Food and Drug Administration. (2014). Grastek prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2017). Odactra prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Stallergenes Greer. (2024). Corporate and product information. Stallergenes Greer.
